Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Gland and Hormone Related Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Digestive System Diseases

Skin and Connective Tissue Diseases

Rare Diseases

Carcinoma, Non-Small-Cell Lung

Thyroid Diseases

Lung Neoplasms

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Pancreatic Neoplasms

Adenocarcinoma

Melanoma

Thyroid Neoplasms

Thyroid Cancer, Papillary

Neoplasms by Histologic Type

Carcinoma

Neoplasms, Glandular and Epithelial

Endocrine Gland Neoplasms

Endocrine System Diseases

Head and Neck Neoplasms

Adenocarcinoma, Papillary

Ovarian Cancer

Ovarian Epithelial Cancer

Pancreatic Cancer

Papillary Thyroid Carcinoma

Antineoplastic Agents

All Drugs and Chemicals

Paclitaxel

Gemcitabine

Fluorouracil

Albumin-Bound Paclitaxel

Nivolumab

Tubulin Modulators

Antimitotic Agents

Antimetabolites

Antineoplastic Agents, Immunological

Immune Checkpoint Inhibitors

Immunosuppressive Agents

Immunologic Factors

Dose escalation of CM24 with nivolumab in adult patients with selected recurrent or metastatic solid tumors

CM-24 and Nivolumab - Dose Escalation

Expansion cohort of CM24 in combination with nivolumab, nab-paclitaxel and gemcitabine in adult patients with advanced metastatic pancreatic cancer

CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion

Expansion cohort of CM24 in combination with nivolumab and Nal-IRI/5-FU/LV in adult patients with advanced metastatic pancreatic cancer

CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion

Expansion cohort of nivolumab in combination with nab-paclitaxel and gemcitabine in adult patients with advanced metastatic pancreatic cancer

Nivolumab, Nab paclitaxel and Gemcitabine - Expansion

Expansion cohort of nivolumab in combination with Nal-IRI/5-FU/LV in adult patients with advanced metastatic pancreatic cancer

Nivolumab and Nal-IRI/5-FU/LV - Expansion

Michael Schickler, PhD

This is an open-label, multicenter, multi-dose escalation and dose expansion study in subjects with selected advanced solid tumors (Part A) and advanced metastatic pancreatic cancer (Parts C \& D) to evaluate the safety and tolerability of CM-24 in combination with nivolumab. In Part C of the study gemcitabine/nab-paclitaxel or Nal-IRI/5-FU/LV will be administered subsequent to CM24 and nivolumab. CM24, nivolumab and gemcitabine/nab-paclitaxel or Nal-IRI/5-FU/LV are administered intravenously.

Parts A and C are non-randomized parts, part D is a randomized part.

A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors

A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors

Incidence of treatment emergent adverse events with CM-24 and nivolumab in adults with selected recurrent or metastatic solid tumors

Incidence of treatment emergent adverse events with CM-24 is used in combination with nivolumab and gemcitabin/nab-paclitaxel or Nal-IRI/5-FU/LV in adults with advanced metastatic pancreatic cancer

This is an exploratory randomized sub-study with the objective of estimating the efficacy of CM24 and nivolumab with chemotherapy (Nal-IRI/5-FU/LV or gemcitabine/ nab-paclitaxel) and chemotherapy only (Nal- IRI/5-FU/LV or gemcitabine/nab-paclitaxel) as measured by overall survival.

Maximum serum concentration \[Cmax\] of CM24

Time of maximum concentration \[Tmax\] of CM24

Area under the serum concentration curve \[AUC\] of CM24

Serum ADA parameters of CM24 as measured by percentage of patients who are positive for the presence of anti-drug antibodies

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors	NCT04731467	Solid Tumor Non Small Cell ... Pancreatic Canc... Ovarian Cancer Papillary Thyro... Melanoma Colorectal Aden...	CM-24 and Nivol... CM-24, Nivoluma... CM-24, Nivoluma... Nivolumab, Nab ... Nivolumab and N...	18 Years -	Purple Biotech Ltd.
A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors	NCT04731467	Solid Tumor Non Small Cell ... Pancreatic Canc... Ovarian Cancer Papillary Thyro... Melanoma Colorectal Aden...	CM-24 and Nivol... CM-24, Nivoluma... CM-24, Nivoluma... Nivolumab, Nab ... Nivolumab and N...	18 Years -	Purple Biotech Ltd.

Spots Global Cancer Trial Database for cm24

Every month we try and update this database with for cm24 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for cm24

Every month we try and update this database with for cm24 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for cm24 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.